Drug Search Results
More Filters [+]

Mebendazole

Alternative Names: mebendazole, vermox, mebendazol, emverm
Latest Update: 2024-12-17
Latest Update Note: Clinical Trial Update

Product Description

Mebendazole is used to treat infections caused by worms. It works by keeping the worm from absorbing sugar (glucose), so that the worm loses energy and dies.  (Sourced from: https://www.mayoclinic.org/drugs-supplements/mebendazole-oral-route/side-effects/drg-20064631?p=1)

Mechanisms of Action: Tubulin Inhibitor,Glucose Uptake Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Hookworm Infections

Known Adverse Events: Abdominal Pain | Pain Unspecified | Stevens-Johnson Syndrome | Agranulocytosis | Neutropenia | Drug Hypersensitivity | Pregnancy Outcomes | Pregnancy, Abdominal | Pregnancy, Prolonged | Anorexia | Diarrhea | Flatulence

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mebendazole

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Astrocytoma|Glioblastoma|Gliosarcoma|Optic Nerve Glioma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CCMC1411

P2

Completed

Glioblastoma|Gliosarcoma|Optic Nerve Glioma|Astrocytoma

2024-04-01

Recent News Events